Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
Antoni RibasAdil I DaudAnna C PavlickRene GonzalezKarl D LewisOmid HamidThomas F GajewskiIgor PuzanovMatthew J WongchenkoIsabelle RooneyJessie J HsuYibing YanErica ParkGrant A McArthurPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
A subset of patients with advanced BRAF V600-mutated melanoma treated with a combination regimen of vemurafenib and cobimetinib achieve favorable long-term outcomes.